|
METTL2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.21150000429193E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.2507000000106E-06 |
| Normal-vs-Stage2 |
2.309900E-02 |
| Normal-vs-Stage3 |
3.6596999875016E-09 |
| Normal-vs-Stage4 |
1.64310000050349E-08 |
| Stage1-vs-Stage2 |
1.289810E-01 |
| Stage1-vs-Stage3 |
4.217600E-02 |
| Stage1-vs-Stage4 |
1.273580E-02 |
| Stage2-vs-Stage3 |
5.437600E-03 |
| Stage2-vs-Stage4 |
4.203300E-03 |
| Stage3-vs-Stage4 |
5.206000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.144799999242E-08 |
| Normal-vs-AfricanAmerican |
4.593900E-02 |
| Normal-vs-Asian |
1.436130E-04 |
| Caucasian-vs-AfricanAmerican |
9.859500E-02 |
| Caucasian-vs-Asian |
7.817000E-01 |
| AfricanAmerican-vs-Asian |
2.346600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.21669999922858E-08 |
| Normal-vs-Female |
3.1430000002608E-07 |
| Male-vs-Female |
1.181410E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.51600000000341E-05 |
| Normal-vs-Age(41-60Yrs) |
6.92760000475801E-08 |
| Normal-vs-Age(61-80Yrs) |
8.97840000013694E-07 |
| Normal-vs-Age(81-100Yrs) |
4.356000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.713830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.819000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.450400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.608600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.928800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.932600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.749900E-02 |
| Classical-VS-Follicular |
7.956800E-01 |
| Classical-VS-Other |
2.002600E-01 |
| Classical-VS-Normal |
3.61829999961927E-07 |
| Tall-VS-Follicular |
8.692200E-02 |
| Tall-VS-Other |
8.304800E-01 |
| Tall-VS-Normal |
8.40070000007742E-07 |
| Follicular-VS-Other |
3.539400E-01 |
| Follicular-VS-Normal |
1.569920E-04 |
| Other-VS-Normal |
4.216700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.96859999995947E-06 |
| Normal-vs-N1 |
1.45280000030112E-07 |
| N0-vs-N1 |
3.812300E-02 |
|
|
